Listing 13.27 Carcinoma of Unknown Primary (CUP) in 2026
Carcinoma of unknown primary (CUP) is a distinct clinical category where a patient presents with metastatic cancer but the primary tumor cannot be identified despite appropriate diagnostic workup. It accounts for about 2-5% of all cancer diagnoses in the United States, representing roughly 15,000-30,000 new cases annually. Historic median overall survival was 3-6 months, though this has improved with molecular tissue-of-origin profiling and tumor-agnostic targeted therapies.
SSA Listing 13.27 covers CUP with automatic qualification once the diagnosis is established. This walkthrough covers the diagnostic workup required to make the CUP diagnosis, the histologic and molecular subtypes, favorable prognostic subsets that get treated as if their most likely primary were known, and the modern treatment approach using molecular tissue-of-origin profiling and broad genomic profiling.
See If You Qualify
The listing text
Automatic qualification after appropriate workup
Listing 13.27 provides automatic qualification for carcinoma with primary site unknown after appropriate search. "Appropriate search" means the medical record documents a reasonable diagnostic workup that failed to identify a primary. Requirements typically include:
- Physical examination including skin, breast (in women), pelvic (in women), rectal, testicular (in men) exams
- Complete blood count and full metabolic panel
- Tumor markers as indicated (PSA in men, AFP, beta-hCG, CA-125, CA 19-9, CEA)
- Cross-sectional imaging: CT chest/abdomen/pelvis
- Mammography in women
- PET-CT in most cases
- Endoscopy (upper and lower) when clinically indicated
- Site-directed imaging based on presentation
- Biopsy of accessible metastatic site with expert pathology review including immunohistochemistry (IHC) panel to narrow origin
Once appropriate workup fails to identify the primary, the diagnosis of CUP is established and the listing is met.
Diagnostic approach
Histologic classification
Light microscopy classifies CUP into:
- Adenocarcinoma (60%) - the largest group, often glandular architecture
- Poorly differentiated carcinoma (30%) - features suggestive of carcinoma but no clear differentiation
- Squamous cell carcinoma (5%) - keratinization, intercellular bridges
- Neuroendocrine carcinoma (small cell or large cell) (1%)
- Other (mixed, undifferentiated)
Immunohistochemistry panel
Standard IHC workup uses broad panel:
- Keratins (AE1/AE3, CK7, CK20) to confirm carcinoma and pattern
- CDX2 (lower GI, some upper GI, appendix)
- TTF-1 (lung adeno, thyroid)
- Napsin A (lung adeno)
- PAX8 (thyroid, kidney, gynecologic)
- ER, PR, GCDFP-15, mammaglobin, GATA3 (breast)
- PSA, NKX3.1 (prostate)
- p40, p63 (squamous)
- Synaptophysin, chromogranin, INSM1 (neuroendocrine)
- HepPar-1, arginase (hepatocellular)
- SALL4, OCT4, SOX2 (germ cell)
- Melanoma markers (S100, SOX10, HMB-45)
- Lymphoid markers to rule out lymphoma
Molecular tissue-of-origin profiling
Two commercial tests now available:
- CancerType ID (Biotheranostics) - 92-gene RT-PCR classifier trained on 50 tumor types
- Prosigna, Tempus xO, Foundation One - various molecular tissue-of-origin platforms
These predict the most likely tissue of origin in about 80-95% of cases, allowing therapy directed at that likely primary rather than empiric CUP chemotherapy.
Broad genomic profiling
Next-generation sequencing panel to identify:
- Targetable mutations for tumor-agnostic therapy (BRAF V600E, NTRK fusions, RET fusions/mutations, MSI-high, TMB-high)
- Common driver mutations suggesting specific tissue of origin (EGFR/ALK for lung, HER2 for breast/gastric)
Favorable CUP subsets (about 15-20% of CUP)
Recognized subsets treated as if the presumed primary were confirmed:
- Squamous cell carcinoma in cervical lymph nodes only: treated as occult head and neck primary with chemoradiation. Good prognosis.
- Single-site axillary lymph node adenocarcinoma in women: treated as occult breast primary with modified radical mastectomy or axillary dissection + radiation + systemic therapy. Good prognosis.
- Peritoneal carcinomatosis in women (papillary serous features): treated as primary peritoneal carcinoma (equivalent to ovarian) with cytoreductive surgery + platinum/taxane +/- PARP inhibitors
- Adenocarcinoma with bone-only metastases in men with PSA-positive: treated as occult prostate primary with ADT
- Poorly differentiated carcinoma with midline distribution in young men: treated as extragonadal germ cell tumor with BEP chemotherapy. Potentially curative.
- Adenocarcinoma with liver-dominant metastases and CDX2+/CK20+: treated as occult GI primary (colorectal-like)
- Neuroendocrine carcinoma of unknown primary: treated per tissue phenotype (small cell vs well-differentiated)
Unfavorable CUP (80-85%)
Metastatic adenocarcinoma or poorly differentiated carcinoma not fitting a favorable subset. Historic median OS 6-9 months with empiric chemotherapy. Modern approach:
- Molecular tissue-of-origin testing to direct therapy
- Broad genomic profiling for tumor-agnostic options
- Immunotherapy for MSI-high (about 2% of CUP), TMB-high (about 10% of CUP), or PD-L1 positive
- Empiric platinum-doublet chemotherapy if no molecular target
Tumor-agnostic FDA approvals available for CUP
- Pembrolizumab: MSI-high solid tumors, TMB-high (10+ mut/Mb) solid tumors
- Dostarlimab: dMMR solid tumors
- Larotrectinib and entrectinib: NTRK fusion-positive solid tumors
- Selpercatinib: RET fusion-positive solid tumors
- Dabrafenib + trametinib: BRAF V600E solid tumors
- Trastuzumab + pertuzumab: HER2-amplified solid tumors (some approvals)
- Erdafitinib: FGFR2/3 alterations (mostly urothelial but tumor-agnostic mechanism)
Immunotherapy and molecular medicine impact
Modern approach with molecular profiling and tumor-agnostic therapy has extended median OS in CUP from 3-6 months (2000s empiric chemo era) to 12-18 months across all comers, with subsets responding to targeted therapy achieving 24+ months.
The Compassionate Allowance overlay
Carcinoma of unknown primary is on the CAL list. Automatic qualification triggers 14-30 day expedited processing.
Worked case examples
Case 1: Robert, 68, Massachusetts, adenocarcinoma bone and liver metastases, molecular tissue of origin predicted lung
Robert presented with lower back pain and 25 lb weight loss January 2026. CT chest/abdomen/pelvis: multiple liver lesions and thoracic spine metastases with no primary. PET-CT confirmed no primary site. Biopsy of liver lesion: moderately differentiated adenocarcinoma. IHC: CK7+, CK20-, TTF-1 weakly positive, other markers negative. CancerType ID predicted lung adenocarcinoma with 78% probability. Broad genomic profiling identified EGFR L858R mutation. Started osimertinib.
SSDI application filed February 2026. Listing 13.27 automatic qualification. Approved 10 days at Massachusetts DDS. Partial response at 3 months.
Case 2: Angela, 58, California, squamous cell carcinoma in cervical lymph nodes only
Angela presented with 3 cm right upper cervical lymph node January 2026. FNA: squamous cell carcinoma. Extensive workup including panendoscopy, PET-CT, biopsies of tongue base and tonsils - no primary identified. p16 positive (HPV associated). Treated per favorable CUP subset as occult HPV-related oropharyngeal primary with chemoradiation (weekly cisplatin + 70 Gy).
SSDI application filed February 2026. Listing 13.27 automatic qualification. Approved 4 weeks at California DDS. Complete response. Chronic xerostomia and dysphagia post-radiation.
Case 3: David, 42, Texas, midline poorly differentiated carcinoma treated as germ cell
David presented with retroperitoneal and mediastinal masses, elevated LDH, weight loss March 2026. Biopsy: poorly differentiated carcinoma. AFP 800, beta-hCG 1,200. IHC: SALL4+, OCT4+, SOX2+ (germ cell markers). Testicular US: no primary. Diagnosed with extragonadal germ cell tumor. Treated with BEP (bleomycin + etoposide + cisplatin) with intent to cure.
SSDI application filed April 2026. Listing 13.27 automatic qualification. Approved 9 days at Texas DDS. Complete response with normalization of markers. Post-chemotherapy retroperitoneal lymph node dissection for residual mass showed teratoma. Chronic pulmonary fibrosis from bleomycin, chronic peripheral neuropathy from cisplatin.
What to file with your application
- Pathology report of biopsied metastatic site with expert review
- Complete IHC panel results
- Molecular tissue-of-origin testing (CancerType ID or equivalent)
- Broad genomic profiling report
- Full imaging workup: CT chest/abdomen/pelvis, PET-CT, mammography, site-directed studies
- Tumor marker panel
- Endoscopy reports if performed
- Documentation that primary site remains unidentified after appropriate workup
- Oncology consultation notes with CUP diagnosis and treatment plan
- Response documentation to any therapy administered
Free eligibility review in 60 seconds.
See If You Qualify
Related reading
Full section walkthrough: Section 13.00 cancer basics. Related cancer listings: 13.14 lung, 13.23 gynecologic, 13.16 esophagus/stomach.
Frequently asked questions
What is carcinoma of unknown primary?
Metastatic cancer where the primary tumor cannot be identified despite appropriate workup. Represents 2-5% of all cancer diagnoses, roughly 15,000-30,000 new US cases per year.
Does CUP automatically qualify for SSDI?
Yes. Listing 13.27 provides automatic qualification once the CUP diagnosis is established through appropriate workup. It is also on the Compassionate Allowance list for 14-30 day expedited processing.
What counts as "appropriate workup"?
Standard workup includes physical exam, cross-sectional imaging (CT chest/abdomen/pelvis), PET-CT in most cases, mammography for women, tumor markers, and biopsy of accessible metastasis with expert pathology + IHC panel. Molecular tissue-of-origin testing and broad genomic profiling are increasingly standard.
Are there favorable CUP subsets?
Yes. About 15-20% of CUP fits recognized favorable subsets: squamous cell carcinoma in cervical nodes (treated as occult head/neck), single-site axillary adenocarcinoma in women (treated as breast), peritoneal carcinomatosis in women (treated as ovarian), midline poorly differentiated carcinoma in young men (treated as germ cell), and others.
What is molecular tissue-of-origin testing?
Commercial tests (CancerType ID, others) that predict the most likely tissue of origin using gene expression profiling in 80-95% of cases. Allows targeted therapy directed at the likely primary rather than empiric CUP chemotherapy.
Are there tumor-agnostic therapies for CUP?
Yes. FDA-approved tumor-agnostic options include pembrolizumab (MSI-high, TMB-high), larotrectinib/entrectinib (NTRK fusions), selpercatinib (RET fusions), dabrafenib + trametinib (BRAF V600E), and dostarlimab (dMMR).
What is the prognosis for CUP?
Historically 3-6 months median OS with empiric chemotherapy. Modern approach with molecular profiling and tumor-agnostic therapy has extended median OS to 12-18 months across all comers, with targeted-therapy responders achieving 24+ months. Favorable subsets treated as occult primaries can be curable.
Next steps
If you were diagnosed with metastatic cancer where the primary site could not be identified after appropriate workup, file for SSDI immediately. Listing 13.27 provides automatic qualification. CAL fast-tracks the initial decision to 14-30 days.